Cervical Cancer Clinical Trials (as in March 2017)

ENGOT-Cx1/BGOG-cx1

Leading group: BGOG

Clinical Trial Study: A randomized phase II trial of paclitaxel-carboplatin 3-weekly with or without Nintedanib (BIBFI 120) in advanced or recurrent cervical carcinoma (I. Vergote)

Number of patients accrued: 49

Planned number of patients: 120

Participating groups:

AGO, GEICO, MaNGO, MITO, NCRI, NOGGO

 

 

ENGOT-Cx2/CEEGOG/SENTIX

Leading group: CEEGOG

Clinical Trial Study: SENTIX (SENTinel lymph node in cervIX cancer) - a prospective observational trial on sentinel lymph node biopsy in patients with early stage cervical cancer

Number of patients accrued: 47

Planned number of patients: 300

Participating groups:

BGOG

 

 

ENGOT-Cx3/CEEGOG/ABRAX

Leading group: CEEGOG

Clinical Trial Study: Abandoning of radical hysterectomy in cervical cancer - retrospective trial

Number of patients accrued: N.A.

Planned number of patients: N.A.

Participating groups: under discussion

 

 

ENGOT-Cx4/GINECO/SENTICOL

Leading group: GINECO

Clinical Trial Study: International prospective validation trial of sentinel node biopsy in cervical cancer

Number of patients accrued: N.A.

Planned number of patients: 900

Participating groups: under discussion

Planned start date end of 2017

 

Up Coming ENGOT Meeting

Frankfurt, Germany, October 12-13, 2017

Don't miss out on the latest updates

Save the Date!

You May Also Like

GCA WORKSHOPS

Watch the Webcasts 

 

Read More

CLINICAL TRIALS

Latest Published Research

 

Read More

FOR PATIENTS

Key Insights

 

Read More

ESGO 2017 Congress

Clinical Trials Session

 

Read More